MedTrace Logo

Pembrolizumab for Newly Diagnosed Glioblastoma

NCT03899857 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2024-05-08

No results posted yet for this study

Summary

The study explores the addition of pembrolizumab to temozolomide-based radiotherapy in patients with newly diagnosed glioblastoma.

Conditions

  • Newly Diagnosed Glioblastoma

Interventions

DRUG

Pembrolizumab

Pembrolizumab will be added to standard of care

Sponsors & Collaborators

Principal Investigators

  • Patrick Roth, MD · University of Zurich

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-21
Primary Completion
2026-04-30
Completion
2026-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03899857 on ClinicalTrials.gov